Abstract
We have developed a novel model for depleting mouse HSCs that has allowed us to clarify their contributions to hepatic injury and fibrosis. Transgenic mice (TG) expressing the herpes simplex virus-Thymidine kinase gene (HSV-Tk) driven by the mouse GFAP promoter were used to render proliferating HSCs susceptible to killing in response to ganciclovir (GCV). Effects of GCV were explored in primary HSCs and in vivo. Panlobular damage was provoked to maximize HSC depletion by combining carbon tetrachloride (CCl4) (centrilobular injury) with allyl alcohol (AA) (periportal injury), as well as in a bile duct ligation (BDL) model. Cell depletion in situ was quantified using dual-immunofluorescence (IF) for desmin and GFAP. In primary HSCs isolated from both untreated wild type (WT) and TG mice, GCV induced cell death in ~50% of HSCs from TG but not WT mice. In TG mice treated with CCl4+AA+GCV, there was a significant decrease in GFAP & desmin positive cells compared to WT mice (~65% reduction, p<0.01), which was accompanied by a decrease in the expression of HSC activation markers (α-SMA, β-PDGFR and collagen I). Similar results were seen following BDL. Associated with HSC depletion in both fibrosis models, there was marked attenuation of fibrosis and liver injury, as indicated by Sirius Red/Fast Green, H&E quantification and serum ALT/AST. Hepatic expression of IL-10 and IFN-γ was increased following HSC depletion. No toxicity of GCV in either WT or TG mice accounted for the differences in injury.
Conclusion
Activated HSCs significantly amplify the hepatic response to liver injury, further expanding this cell type's repertoire in orchestrating hepatic injury and repair.
Keywords: Herpes simplex virus-Thymidine kinase (HSV-Tk), carbon tetrachloride (CCl4), fibrosis, apoptosis, bile duct ligation (BDL)
Hepatic stellate cells (HSCs) are well-characterized non-parenchymal cells of the liver with established roles in fibrosis, repair and immunity (1). During liver injury, quiescent HSCs undergo activation, secreting a repertoire of molecules involved in cell proliferation, chemotaxis, inflammation and fibrosis, among others. Although their role in fibrogenesis is well established, the contributions of HSCs to acute hepatocellular damage and tissue homeostasis are not well understood.
Models to manipulate HSC function or number offer an appealing strategy to clarify this issue. However, only two models have been established to deplete HSCs in vivo thus far, by using gliotoxin (2) or gliotoxin-coupled antibodies against synaptophysin (3, 4). Gliotoxin reportedly induces selective apoptosis of HSCs by subverting NF-κB-mediated survival (2), and can reduce fibrosis and enhance resolution in experimental models, especially when targeted using HSC-specific antibodies (3–5). However, gliotoxin also has broad actions in vivo and in culture, targeting not only HSCs but also immune and endothelial cells and hepatocytes (5, 6).
An alternative strategy is to ectopically express the herpes simplex virus-thymidine kinase (HSV-Tk) gene in target cells, which renders them susceptible to killing by the antiviral agent ganciclovir (GCV), but only when the cells are proliferating. This possibility was first reported as an anti-cancer approach (7) and further refined (8) in murine sarcoma and lymphoma cells, provoking both apoptotic and non-apoptotic cell death (9, 10). The approach has also been reported in liver injury models and in cultured HSCs (11), but has not been used to deplete HSCs in vivo (12).
We have exploited this strategy by using mice expressing the HSV-Tk gene driven by the GFAP promoter, which is a marker of HSCs in rodent liver (1). The approach has uncovered a novel and unexpected role for HSCs in amplifying acute liver injury.
Experimental procedures
(Further information is provided in Supplemental Materials and Methods)
Animals
Seven to eight week-old male Gfap-Tk mice (B6.Cg-Tg(Gfap-Tk)7.1Mvs/J, Jackson Laboratory, Bar Harbor, ME) were used for in vivo experiments in accordance with Institutional Animal Care and Use Committee Protocols. Transgenic mice (TG) express the herpes-simplex virus Thymidine kinase gene (HSV-Tk) driven by the mouse glial fibrillary acidic protein (GFAP) promoter. HSV-Tk negative littermates served as controls (WT).
In vivo liver injury models for HSC depletion
All treatment schemes are depicted in Supplemental Figure 1. Carbon tetrachloride (CCl4) and allyl alcohol (AA) were purchased from Sigma-Aldrich (MO, USA). Mice were treated with CCl4 (0.25 μL/g, i.p. diluted in 50 μL corn oil, on day 1, 4, 7, and 10) and allyl alcohol (0.0125 μL/g i.p. diluted in 100 μL 0.9% NaCl, on day 2, 5, 8) to induce acute liver injury and optimize HSC proliferation while evoking only modest liver damage. To induce selective killing of HSV-Tk-expressing HSCs, ganciclovir (GCV) (Cytovene, CA) was administrated from day 3 to day 11 (100 μg/g, i.p. diluted in 0.9% NaCl), n=6.
For bile duct ligation, 8–12 week old mice underwent BDL or sham surgery as previously described (13). WT and TG animals received 100 μg/g/d GCV i.p. diluted in 0.9% NaCl (or 0.9% NaCl alone for sham animals) beginning the day after surgery for 11 consecutive days. At least 5 animals were treated per BDL group (n=5); sham+GCV (n=3), sham+saline (n=2).
Cell lines and cultures
The murine hepatic stellate cell line JS1 has been previously described (14), the mouse hepatocyte cell line AML12 was purchased from ATCC (VA, USA) and the immortalized endothelial cell line TSEC was kindly donated by Vijay Shah, MD (15).
Isolation and culture of primary HSCs and hepatocytes
Mouse HSCs were isolated by in situ perfusion of livers with collagenase and pronase, and Percoll™ gradient centrifugation. Primary hepatocytes were isolated by in situ perfusion with collagenase, followed by differential centrifugation.
Histological analysis
Histological liver analysis performed by an expert pathologist (I.F.) using a score from 0–3 for both centrilobular and parenchymal necrosis, according to the following: 0.None, 1.Isolated hepatocytes, 2.Groups of hepatocytes, 3.Bridging. Ballooning of hepatocytes was scored as follows: 0.None, 1.Mild, 2.Moderate, 3.Severe. For each mouse,10 fields at 100× magnification were analyzed and the average was calculated for each mouse.
Statistical analysis
Unless otherwise stated, data represent mean ± SEM. Statistical analysis was performed by SPSS® software (version 17, IL, USA). Significance was calculated by Student's t-test or, when appropriated, by analysis of variance (ANOVA). Differences were considered significant if p<0.05.
Results
Validation of the HSV-Thymidine kinase (HSV-Tk) expression and specific ganciclovir (GCV) toxicity towards cultured primary cells
RT-PCR was performed on mRNA extracted from whole liver and HSCs isolated from both wild type (WT) and GFAP-HSV-Tk (TG) mice. Only TG samples consistently expressed the HSV-Tk transcript for up to 7 days in primary culture (Supplementary Figure 2A). HSV-Tk expression was absent from both WT and TG primary hepatocytes (data not shown).
Optimization of GCV dose in cultured cells
In initial studies, we first established a dose-dependent toxicity curve for GCV in established murine cell lines, and then applied the same concentrations to primary HSCs isolated from WT and TG mice. Both immortalized mouse stellate cells (JS1) cells and hepatocytes (AML12) were incubated with incremental GCV concentrations for 3 days. GCV-mediated toxicity unrelated to HSV-Tk gene expression was analyzed by assessing 3H-thymidine incorporation, and AlamarBlue Assay. Cell death was determined by staining with trypan blue and determining the percentage of viable cells. Using this approach, GCV doses higher than 10 μM were toxic in cell lines (Supplementary Figure 2B–D), and subsequent experiments in primary cells therefore used 5 μM GCV, which avoided non-specific toxicity.
Next, primary HSCs from both WT and TG mice were cultured for 5 days with GCV (5 μM and 500 μM) or saline. Specific GCV toxicity was determined by measuring 3H-thymidine incorporation and trypan blue staining (Figure 1A, B). Only TG HSCs exhibited significantly decreased thymidine incorporation and cell survival, indicating specific GCV-mediated killing at 5 μM, thus validating the construct for use in vivo.
To further establish the specificity of GCV, we also isolated primary hepatocytes from both WT and TG mice, incubating them with GCV at the same concentrations (5 μM and 500 μM). In primary hepatocytes, 5 μM GCV had no impact on the cells, whereas 500 μM GCV remained toxic, highlighting the specificity of cell killing at the 5 μM concentration (Supplementary Figure 2E). Immortalized endothelial cells (TSEC) treated with the same GCV doses behaved identically to primary hepatocytes, with no decrease in 3H-thymidine incorporation at 5 μM GCV but a significant effect at 500 μM (Supplementary Figure 2F).
GCV kills HSV-Tk-expressing HSCs by apoptosis
We next determined the mechanism underlying the GCV-mediated killing of TG HSCs by measuring PARP cleavage by Western blot as a reflection of apoptosis. Using this approach, only TG HSCs treated with GCV displayed specific PARP cleavage (Figure 1C). Transgenic HSC killing was also completely inhibited by the pan-caspase inhibitor z-VAD-fmx, further establishing apoptosis as the underlying mechanism of GCV-mediated killing (Figure 1D).
Optimization of HSC depletion in vivo following GCV administration
We next established the specificity of GCV effects in vivo. A dose range was performed by administering GCV in different concentrations (20–150 μg/g body weight), ip daily for up to 10 days in WT and TG mice. None of these mice displayed behavioral or morphological changes (data not shown), or any increase in serum ALT levels (Supplementary Figure 3A). In contrast, more prolonged treatments using higher doses of GCV (≥150 μg/g) led to a significant decrease in weight in TG, but not WT mice (Supplementary Figure 3B). This finding, together with previously published studies (16), led us to choose a final dose of 100 μg/g in subsequent experiments to deplete TG HSCs in vivo.
Because HSCs must be proliferating to render them susceptible to GCV-mediated killing, we next optimized the method of liver injury required to maximize HSC depletion. To do so, we used CCl4 and allyl alcohol (AA) to induce selective injury to the centrilobular and periportal regions, respectively. Accordingly, we performed a dose-dependent toxicity curve after 4 doses of AA (every 3 days) choosing 0.0125 μL/g as the final dose, based on mouse survival, the extent of HSC activation (α-SMA IHC) and liver damage (H&E), to provoke the most widespread HSC proliferation while minimizing hepatocyte damage (Supplementary Figure 4). A dose of 0.25 μL/g CCl4 in 50 μL oil was used to optimize centrilobular HSC activation. The treatment scheme is depicted in Supplemental Figure 1A.
Validation of HSC depletion in TG mice
In TG mice treated with CCl4+AA+GCV (“depletion treatment”), there was a significant decrease of desmin and GFAP co-expressing cells with a reduction of ~65%, p<0.01 as assessed by immunofluorescence co-localization analysis compared to WT mice receiving the same treatment (Figure 2A and Supplementary Figure 5). This decrease in protein expression was accompanied by a reduction of GFAP mRNA in mice undergoing HSC depletion (Figure 2B).
To further analyze the efficacy of the depletion treatment, we assessed markers of HSC activation, including α-SMA immunohistochemistry, and β-PDGFR and collagen I mRNA quantification. Figure 3A displays a >90% depletion of α-SMA positive cells in TG animals with HSC depletion, compared to WT mice. Consistently, β-PDGFR and collagen I mRNA expression levels were decreased in TG mice following HSC depletion, compared to WT mice (Figure 3B). Of interest, CXCR4 has been recently implicated in HSC activation (17), and its mRNA expression in TG mice undergoing HSC depletion was also reduced (Figure 3C).
We confirmed these findings in a bile duct ligation (BDL) model. BDL (or sham) was performed in WT and Tg mice (n=5) (Supplementary Figure 1B). Mice received 100 μg/g/d GCV ip. (or 0.9% NaCl) for 11 days. In Tg mice that had been treated by BDL+GCV, desmin positive cells were significantly decreased compared to WT mice, indicating that activated GFAP-expressing fibrogenic cells proliferate following BDL as well, and that these cells can therefore be successfully depleted in BDL by GCV in Gfap-HSV-Tk+ mice (Supplementary Figure 6).
To determine if apoptosis accounted for HSC depletion in vivo as in culture, we performed TUNEL staining in mice that had been treated with CCl4+AA+GCV for 4 days instead of 10 days, since we expected the number of HSCs undergoing apoptosis to be higher at this time point. Indeed, at 4 and 7 days, HSC depletion was evident (reduction of ~ 40% and 50%, respectively, p<0.05) albeit to a lower extent (Supplementary Figure 7). As anticipated, a significant increase in non-parenchymal TUNEL-positive cells was evident in TG mice compared to WT animals after the depletion treatment (Supplementary Figure 8A). To further establish that these non-parenchymal TUNEL positive cells were HSCs, we analyzed serial sections with staining for TUNEL and desmin (Supplementary Figure 8B), which demonstrated apparent expression by the same cells, although double immunofluorescence and confocal microscopy would be required for strict confirmation of co-expression.
Of interest, HSC depletion with CCl4+AA+GCV was not accompanied by any detectable non-liver effects of GCV on other GFAP-expressing populations. Specifically, there were no differences in animal behavior, survival at 30 days, leukocyte counts, serum creatinine, Cyp2E1 activity (which metabolizes CCl4 and allyl alcohol) (Supplementary Figure 9) or macroscopic or microscopic gastrointestinal appearance following HSC depletion (Supplementary Figure 10). Specifically, there was no edema, necrosis, or inflammation in the bowel of either WT and TG mice. Complementary, intestinal decontamination reported same results regarding HSC depletion (data not shown), excluding the possibility for an altered gut permeability as a possible cause.
Functional consequences of HSC depletion
Having established a specific, reproducible method of HSC depletion, we next explored the functional impact of HSC loss on fibrosis, liver injury, and hepatic inflammation in the two models.
Attenuated hepatic fibrosis
Because activated HSCs are the main collagen-producing cell during liver injury, we assessed fibrosis by collagen morphometry following their depletion. Following 11 days of CCl4+AA+GCV treatment, collagen deposition was significantly decreased in GFAP-HSV-Tk mice compared to WT animals as determined by Sirius Red/Fast Green staining and morphometry (Figure 4A). This finding could also be observed in mice treated with BDL+GCV (see Figure 4B).
Reduced hepatic injury
There was a significant diminution in the extent of liver necrosis after HSC depletion in TG by both fibrosis models based on histology and serum chemistry. Blinded pathologic scoring revealed significantly decreased scores for necrosis for both CCl4+AA+GCV (Figure 5A) and BDL+GCV treated TG animals (Figure 5B), thus underscoring the applicability of this deletion approach to two mechanistic distinct fibrosis models. AST/ALT levels were significantly reduced in CCl4+AA+GCV treated animals indicating less liver injury (Figure 6A). The same trend could be observed for BDL+GCV treated animals (Figure 6B) while no significant differences were observed in serum total billirubin or total protein (data not shown). Consistent with histological results there was a significantly reduced expression of HMGB1 (a marker of hepatic injury (18)) in TG animals with HSC depletion (Supplementary Figure 11). The extent of hepatic injury (as assessed by histology scores for centrilobular necrosis, ballooning, serum AST/ALT levels) coincided temporally with the extent of HSC depletion in mice treated for 0, 4 and 7 days with CCl4+AA+GCV, reinforcing the role of HSCs in provoking injury (Supplementary Figure 12).
To address potential sources of decreased liver damage, we analyzed a marker of lipid peroxidation, 4-hydroxy-2-nonenal (4-HNE) by immunoblotting in whole liver lysates from CCl4+AA+GCV animals, which revealed a significant decrease in 4-HNE-modified proteins in TG mice undergoing HSC depletion (Figure 6C).
We also determined if HSC depletion can be maintained for up to one month by continuing a depletion treatment with reduced doses of CCl4 and GCV in order to evaluate the impact on survival rates, non-liver effects, fibrosis and damage (treatment summarized in Supplemental Figure 1C). Consistent with previous results, there remained a statistically significant decrease in fibrosis (Figure 7A) and liver damage as assessed by histological necrosis scores (Figure 7B) and ALT levels (Figure 7C) in TG mice. Interestingly, an increase in ballooning degeneration was evident in TG mice whereas there was a decrease in centrilobular necrosis. There were no significant differences in overall survival or weight loss in TG or WT mice (data not shown).
Altered intrahepatic leukocyte population and intrahepatic cytokine expression
An initial screen using a cytokine bead array assay revealed induction of two key anti-inflammatory cytokines, IL-10 and IFN-γ in CCl4+AA+GCV HSC depleted TG mice (Figure 8A), and of IL-10 but not IFN-γ in BDL+GCV treated TG mice (Figure 8B). No changes in IL-6 or TNF-α concentrations were observed (data not shown). To characterize possible sources of IL-10 and IFN-γ we analyzed intrahepatic leukocyte populations and performed polychromatic flow cytometry analysis. Dendritic cells, natural killer cells and CD4+ and CD8+ T cells, major potential sources of IFN-γ, were significantly increased in TG HSC depleted mice. Among immune cells that produce IL-10, both Tregs and Ly6C+/F4/80+/CD11b+ cells were significantly recruited to the liver during HSC depletion (Supplementary Figure 13).
Discussion
Ongoing efforts have attempted to target HSCs with cell-specific reagents as a potential diagnostic or therapeutic tool. Concomitantly, cell-specific depletion has been exploited in other cell types to establish their contribution to organ homeostasis (e.g, macrophages), with a few studies examining HSC depletion (2–5). To date, these investigations have reinforced the HSC's known role in fibrogenesis but have not expanded their repertoire of potential contributions to liver injury and inflammation. Gliotoxin, even when targeted to HSCs by coupling to antibodies to synaptophysin, could have broad actions in vivo on immune cells that have not been characterized thoroughly yet, for example by analyzing for macrophage markers other than F4/80+ (e.g. CD68) or by FACS analysis of intrahepatic leukocytes (3, 4).
We report here a new murine model of HSC depletion that uncovers a previously unknown role in amplifying liver injury, using mice expressing the HSV-Tk gene driven by the mouse GFAP promoter. This system restricts cell depletion to proliferating HSCs, thereby uncovering the impact of only activated HSCs to liver injury and repair, because quiescent, non-proliferating HSCs are not affected.
Initial analyses confirmed reduced HSC proliferation (~50%) and increased apoptosis in isolated, cultured HSCs from TG mice when treated with GCV, consistent with previous studies utilizing the HSV-Tk `suicide gene' strategy (12), and mimicking the natural fate of HSC during resolution acute liver damage (19). Of note, approximately 70% of HSCs express GFAP (20), so that GCV-mediated killing affects the majority, but not all HSCs. Importantly, neither hepatocytes from either WT or TG mice, nor immortalized sinusoidal endothelial cells were depleted by the same treatment, reinforcing the cellular specificity of this model. Because GFAP-HSV-Tk is expressed in specific cells outside the liver (e.g., enteric glial cells) we excluded the possibility that the liver effects resulted from the loss of GFAP-expressing cells in other tissues or altered metabolism. Lethal effects of GCV (16) were reported after 14 days of continuous treatment with GCV (100 μg/g/d) via a subcutaneous pump in these mice. We therefore limited the GCV treatment to 11 days administered once daily i.p. Based on its pharmacokinetics, toxic serum levels of GCV are expected to be of a much shorter duration, therefore minimizing adverse effects. Indeed, we did not see increased lethality or mortality, or altered small bowel pathology with our treatment scheme.
Once in vivo HSC depletion was achieved, its functional impact was assessed by measuring markers of HSC activation. There was a dramatic decrease in α-SMA positive cells in TG mice undergoing HSC depletion, together with other markers of HSC proliferation (ie., β-PDGFR and collagen I), indicating that depletion affected those HSCs most critical to fibrogenesis and repair (i.e. activated HSCs). Of interest, CXCR4 expression was also decreased in TG mice undergoing HSC depletion. This cytokine receptor is another feature of activated HSCs, which also contributes to profibrogenic and proliferative responses (17).
The findings reinforce the rationale for therapeutic HSC depletion, albeit not necessarily by a suicide gene strategy. Moreover, not only was fibrosis reduced, but acute damage was attenuated, suggesting that depletion of activated HSCs could have dual salutary effects on both the amount of fibrosis and extent of injury. Correlated with attenuated injury was a reduction in 4-HNE consistent with decreased oxidant stress, although the source(s) of these pro-oxidants in both WT and TG mice are not clarified by our findings. Specifically, reduction in 4-HNE could reflect decreased release by HSCs because of their depletion, or loss of paracrine signals from HSCs to other cell types that generate 4-HNE, including hepatocytes or inflammatory cells. Moreover, 4-HNE interacts directly with JNK isoforms in human HSCs to stimulate pro-collagen type I expression and synthesis (21). Thus, reduced collagen production could also result from a feedback loop in which less 4-HNE leads to less JNK-mediated collagen expression. Of note, previous studies using gliotoxin did not uncover an impact of HSC depletion on injury (2, 5), possibly because effects of gliotoxin are not as specific, and concurrent effects of gliotoxin on other cell types might have attenuated the phenotype.
The mechanism of attenuated injury in the setting of HSC depletion is not fully clarified, but the increase in IL-10 and IFN-γ likely contribute to reduced injury, since these two cytokines both down-regulate HSC activation and fibrosis production (22). Polychromatic flow cytometry for intrahepatic immune cell populations revealed increased numbers of well known cellular sources of IL-10 (Tregs and monocytes) (23) as well as for IFN-γ (DC, NK, CD4+ and CD8+ T cells) (24). Specifically, the increase in Tregs along with an increase of IL-10, which unlike IFN-γ was evident in both HSC depletion models, indicates a potential role for Tregs in the attenuation of liver injury despite increased numbers of several immune cell populations in the absence of HSCs. Further studies to analyze these preliminary findings and to identify the responsible immune cell population by specific depletion studies in vivo are currently underway.
Importantly, injury was attenuated following HSC depletion not only in acute, but also in chronic injury (30 days after HSC depletion with continued CCl4 and GCV) as well as in the BDL fibrosis model, indicating that the results are generalizable and not restricted to a single model of injury. Mice with HSC depletion after chronic injury all survived, attesting to the practicality of chronic HSC depletion with this strategy. Interestingly, the reduced injury in TG mice was associated with more hepatocyte ballooning, raising the prospect that ballooning degeneration but not necrosis could be beneficial, as ballooning has been previously proposed to indicate a better chance of cellular recovery after injury (25).
Our studies further suggest that HSCs (and not portal myofibroblasts, which reportedly not express GFAP (26) and are therefore not ablated in this model) are the major fibrogenic cell population in BDL-induced fibrosis consistent with an earlier study analyzing HSCs in different models by microarray (27).
In conclusion, we describe a new approach to HSC depletion that has confirmed the primacy of these cells in fibrosis production, but has also revealed an unexpected role in amplifying hepatocellular liver damage and decreasing protective cytokines. The model offers the prospect of exploring other features of liver homeostasis that may depend on HSCs, including their repopulation from extrahepatic sources and their contribution to hepatic regeneration and neoplasia.
Supplementary Material
Acknowledgements
We thank Drs. Virginia Hernandez Gea, and Feng Hong and Stephanie Gillespie for technical support, Dr. Vijay Shah for his generous donation of TSEC cells and Dr. Inma Castilla de Cortázar for her helpful advice.
Financial Support: Supported by funds from the Alfonso Martin Escudero Fundation (to J.P), the Deutsche Forschungsgemeinschaft (DFG) (to Y.L.) and NIH grants DK56621 & P20AA017067 (to S.L.F.).
List of Abbreviations
- 4-HNE
4-hydroxy-2-nonenal
- α-SMA
alpha smooth muscle actin
- GCV
ganciclovir
- GFAP
glial fibrillary acidic protein
- HMGB1
high-mobility group protein B1
- HSC
hepatic stellate cell
- HSV-Tk
herpes simplex virus-Thymidine kinase
Footnotes
Conflict of interest The authors have nothing to disclose.
References
- 1.Friedman SL. Hepatic Stellate Cells – Protean, Multifunctional, and Enigmatic Cells of the Liver. Physiological Reviews. 2008;88:125–172. doi: 10.1152/physrev.00013.2007. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Orr JG, Leel V, Cameron GA, Marek CJ, Haughton EL, Elrick LJ, Trim JE, et al. Mechanism of action of the antifibrogenic compound gliotoxin in rat liver cells. Hepatology. 2004;40:232–242. doi: 10.1002/hep.20254. [DOI] [PubMed] [Google Scholar]
- 3.Ebrahimkhani MR, Oakley F, Murphy LB, Mann J, Moles A, Perugorria MJ, Ellis E, et al. Stimulating healthy tissue regeneration by targeting the 5-HT2B receptor in chronic liver disease. Nat Med. 2011;17:1668–1673. doi: 10.1038/nm.2490. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Douglass A, Wallace K, Parr R, Park J, Durward E, Broadbent I, Barelle C, et al. Antibody-targeted myofibroblast apoptosis reduces fibrosis during sustained liver injury. J Hepatol. 2008;49:88–98. doi: 10.1016/j.jhep.2008.01.032. [DOI] [PubMed] [Google Scholar]
- 5.Hagens WI, Olinga P, Meijer DK, Groothuis GM, Beljaars L, Poelstra K. Gliotoxin non-selectively induces apoptosis in fibrotic and normal livers. Liver Int. 2006;26:232–239. doi: 10.1111/j.1478-3231.2005.01212.x. [DOI] [PubMed] [Google Scholar]
- 6.Anselmi K, Stolz DB, Nalesnik M, Watkins SC, Kamath R, Gandhi CR. Gliotoxin causes apoptosis and necrosis of rat Kupffer cells in vitro and in vivo in the absence of oxidative stress: exacerbation by caspase and serine protease inhibition. J Hepatol. 2007;47:103–113. doi: 10.1016/j.jhep.2007.02.024. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Moolten FL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res. 1986;46:5276–5281. [PubMed] [Google Scholar]
- 8.Moolten FL, Wells JM. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J Natl Cancer Inst. 1990;82:297–300. doi: 10.1093/jnci/82.4.297. [DOI] [PubMed] [Google Scholar]
- 9.Qian C, Bilbao R, Bruna O, Prieto J. Induction of sensitivity to ganciclovir in human hepatocellular carcinoma cells by adenovirus-mediated gene transfer of herpes simplex virus thymidine kinase. Hepatology. 1995;22:118–123. [PubMed] [Google Scholar]
- 10.Fillat C, Carrio M, Cascante A, Sangro B. Suicide gene therapy mediated by the Herpes Simplex virus thymidine kinase gene/Ganciclovir system: fifteen years of application. Curr Gene Ther. 2003;3:13–26. doi: 10.2174/1566523033347426. [DOI] [PubMed] [Google Scholar]
- 11.Zhang Y, Huang SZ, Wang S, Zeng YT. Development of an HSV-tk transgenic mouse model for study of liver damage. FEBS J. 2005;272:2207–2215. doi: 10.1111/j.1742-4658.2005.04644.x. [DOI] [PubMed] [Google Scholar]
- 12.Janoschek N, van de Leur E, Gressner AM, Weiskirchen R. Induction of cell death in activated hepatic stellate cells by targeted gene expression of the thymidine kinase/ganciclovir system. Biochem Biophys Res Commun. 2004;316:1107–1115. doi: 10.1016/j.bbrc.2004.02.147. [DOI] [PubMed] [Google Scholar]
- 13.Kountouras J, Billing BH, Scheuer PJ. Prolonged bile duct obstruction: a new experimental model for cirrhosis in the rat. Br J Exp Pathol. 1984;65:305–311. [PMC free article] [PubMed] [Google Scholar]
- 14.Guo J, Hong F, Loke J, Yea S, Lim CL, Lee U, Mann DA, et al. A DDX5 S480A polymorphism is associated with increased transcription of fibrogenic genes in hepatic stellate cells. J Biol Chem. 2010;285:5428–5437. doi: 10.1074/jbc.M109.035295. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Huebert RC, Jagavelu K, Liebl AF, Huang BQ, Splinter PL, Larusso NF, Urrutia RA, et al. Immortalized liver endothelial cells: a cell culture model for studies of motility and angiogenesis. Lab Invest. 2010 doi: 10.1038/labinvest.2010.132. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Bush TG, Savidge TC, Freeman TC, Cox HJ, Campbell EA, Mucke L, Johnson MH, et al. Fulminant jejuno-ileitis following ablation of enteric glia in adult transgenic mice. Cell. 1998;93:189–201. doi: 10.1016/s0092-8674(00)81571-8. [DOI] [PubMed] [Google Scholar]
- 17.Hong F, Tuyama A, Lee TF, Loke J, Agarwal R, Cheng X, Garg A, et al. Hepatic stellate cells express functional CXCR4: role in stromal cell-derived factor-1alpha-mediated stellate cell activation. Hepatology. 2009;49:2055–2067. doi: 10.1002/hep.22890. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Liu A, Jin H, Dirsch O, Deng M, Huang H, Brocker-Preuss M, Dahmen U. Release of danger signals during ischemic storage of the liver: a potential marker of organ damage? Mediators Inflamm. 2010;2010:436145. doi: 10.1155/2010/436145. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Elsharkawy AM, Oakley F, Mann DA. The role and regulation of hepatic stellate cell apoptosis in reversal of liver fibrosis. Apoptosis. 2005;10:927–939. doi: 10.1007/s10495-005-1055-4. [DOI] [PubMed] [Google Scholar]
- 20.Geerts A. History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. Semin Liver Dis. 2001;21:311–335. doi: 10.1055/s-2001-17550. [DOI] [PubMed] [Google Scholar]
- 21.Parola M, Robino G, Marra F, Pinzani M, Bellomo G, Leonarduzzi G, Chiarugi P, et al. HNE interacts directly with JNK isoforms in human hepatic stellate cells. J Clin Invest. 1998;102:1942–1950. doi: 10.1172/JCI1413. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Pinzani M, Marra F. Cytokine receptors and signaling in hepatic stellate cells. Semin Liver Dis. 2001;21:397–416. doi: 10.1055/s-2001-17554. [DOI] [PubMed] [Google Scholar]
- 23.Ma G, Pan PY, Eisenstein S, Divino CM, Lowell CA, Takai T, Chen SH. Paired immunoglobin-like receptor-B regulates the suppressive function and fate of myeloid-derived suppressor cells. Immunity. 2011;34:385–395. doi: 10.1016/j.immuni.2011.02.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Billiau A, Matthys P. Interferon-gamma: a historical perspective. Cytokine Growth Factor Rev. 2009;20:97–113. doi: 10.1016/j.cytogfr.2009.02.004. [DOI] [PubMed] [Google Scholar]
- 25.Bergasa NV, Borque MJ, Wahl LM, Rabin L, Jones EA. Modulation of thioacetamide-induced hepatocellular necrosis by prostaglandins is associated with novel histologic changes. Liver. 1992;12:168–174. doi: 10.1111/j.1600-0676.1992.tb01042.x. [DOI] [PubMed] [Google Scholar]
- 26.Iwaisako K, Brenner DA, Kisseleva T. What's new in liver fibrosis? The origin of myofibroblasts in liver fibrosis. J Gastroenterol Hepatol. 2012;27(Suppl 2):65–68. doi: 10.1111/j.1440-1746.2011.07002.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.De Minicis S, Seki E, Uchinami H, Kluwe J, Zhang Y, Brenner DA, Schwabe RF. Gene expression profiles during hepatic stellate cell activation in culture and in vivo. Gastroenterology. 2007;132:1937–1946. doi: 10.1053/j.gastro.2007.02.033. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.